Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Israel

European Innovation Council · Running

ReLiV Real time Liver disease early diagnosis through exhaled Volatile Organic Compounds sensing

Coordinator
Nanose Medical Ltd, Israel
Runs
1 May 2024 to 30 April 2027
Status
Running
EU funding
€2.5m
Total cost
€2.5m
Partners
1 organisations in 1 countries
Type
European Innovation Council
Grant agreement
101158688

What the project is doing

In the project's own words, from its summary on CORDIS.

The analysis of volatile organic compounds (VOCs) in exhaled breath with nano sensors has great potential to transform healthcare, with accurate, inexpensive, real-time diagnostics. However, attempts to implement this strategy have failed to reach clinical deployment. Firstly, many efforts try to identify the complex mixture of VOCs associated with disease, which is a long and expensive process. Secondly, commercially available sensors require high operating temperatures and have low sensitivity to breath VOCs.

NaNose Medical has overcome these limitations through DiaNose, an easy to use, hand-held diagnostics device with potential applicability in >20 different diseases. Instead of identifying individual VOCs, DiaNose deploys an array of patented cross-reactive sensors delivering a chemical signature of breath that can be classified as healthy or diseased through artificial intelligence. Our initial alpha prototype focuses on a key clinical indication: Non-Alcoholic Fatty Liver Disease (NAFLD): with a global prevalence of 30%, it is the leading cause of liver related morbidity, generating an annual burden in Europe of > €35 billion and a further €200 billion of societal costs.

Crucially, NAFLD diagnostics present key limitations: liver biopsies are expensive, invasive and subject to sampling error, and non-invasive alternatives lack precision, are operator-dependent, and require expert interpretation. DiaNose will fill this gap, aiming to achieve a diagnostic accuracy of >90% at <50€/test. Lab testing of our alpha prototype has shown high accuracy (88%) with NAFLD models. With the ReLiV project, we will develop an advanced beta prototype that will be validated in clinical settings across different locations.

This will bring DiaNose one step closer to commercialization, providing a truly cost-effective, point-of-care detection and monitoring device capable of improving patient outcomes and alleviating the economic burden generated by the growing NAFLD pandemic.

Topics

Who is involved

OrganisationCityCountryRole
Nanose Medical LtdNetanyaIsraelCoordinator

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI